Announcements

Conference: The 146th Annual Meeting of the Pharmaceutical Society of Japan (Osaka)
Date: 26–29 March 2026
Location: Osaka, Japan

MDPI will be attending the 146th Annual Meeting of the Pharmaceutical Society of Japan (Osaka) as an exhibitor, which will be held from 26 to 29 March 2026, and we welcome researchers from diverse backgrounds to visit and share their latest ideas with us.

Pharmaceutical sciences are comprehensive sciences that require expertise from a wide range of academic fields, including physics, chemistry, biology, medical sciences, and clinical sciences. In order to overcome the various challenges surrounding pharmaceutical sciences today, cross-disciplinary collaboration beyond traditional boundaries has become increasingly important and will be emphasized and discussed during the 146th Annual Meeting of the Pharmaceutical Society of Japan (Osaka).

The conference is organized by the Pharmaceutical Society of Japan and chaired by Prof. Takashi Ohshima from the Graduate School of Pharmaceutical Sciences, Kyushu University. The theme is Promoting the Ecosystem in Pharmaceutical Sciences: Future Innovation through Cross-disciplinary Collaboration. This conference will bring together around 5,000 scientists and students to share research advances covering a wide range of scientific topics. The sessions include, but are not limited to, the following: (1) Pharmaceutical Chemistry; (2) Pharmaceutical Physics; (3) Pharmaceutical Biology; (4) Pharmaceutical Health Science and Environmental Toxicology; (5) Pharmaceutical Health Care and Sciences; and (6) Others.

The following MDPI journals will be represented at the conference:

• Pharmaceuticals;
• Diseases;
• Pharmacy;
• Applied Biosciences;
• Antibodies;
• Biomedicines;
• Future Pharmacology;
• JPBI;
• JPM;
• Marine Drugs;
• Medicines;
• Pharmaceutics;
• Pharmacoepidemiology.

Conference: 5th MMCS: New Trends in Chemical Biology and Drug Discovery
Date: 14–17 May 2026, Beijing Time
Conference website: https://sciforum.net/event/MMCS2026

This conference is organized by the MDPI journal Molecules (ISSN: 1420-3049, IF: 4.2, and CiteScore: 7.4) and will take place in Beijing, China, from 14 to 17 May 2026 (Beijing time).

Conference Chairs:

• Prof. Dr. Xiaoguang Lei, College of Chemistry and Molecular Engineering, Peking University, China;
• Prof. Dr. Diego Muñoz-Torrero, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Spain.

Topics of interest:
S1. Chemical biology for drug discovery;
S2. AI for drug discovery;
S3. New proximity-based drug modalities;
S4. Natural products in drug discovery;
S5. Biocatalysis for natural product and drug synthesis;
S6. Drug discovery targeting GPCRs and ion channels;
S7. DNA-encoded libraries in drug discovery;
S8. Medicinal chemistry tales.

Important dates:
Deadline for abstract submission: 13 March 2026;
Abstract acceptance notification: 27 March 2026;
Early bird registration deadline: 3 April 2026;
Covering author registration deadline: 3 April 2026;
Registration deadline: 14 May 2026.

Guide for authors:

To submit your abstract, please visit the following link: https://sciforum.net/user/submission/create/1319.

To register for the event, please visit the following link: https://sciforum.net/event/MMCS2026?section=#registration.

For more information, you may refer to the following link: https://sciforum.net/event/MMCS2026.

For any inquiries regarding the event, please contact mmcs2026@mdpi.com.

We look forward to seeing you at the 5th MMCS: New Trends in Chemical Biology and Drug Discovery.

MDPI is delighted to announce the establishment of the Michele Parrinello Award. Named in honor of Professor Michele Parrinello, the award celebrates his exceptional contributions and his profound impact on the field of computational physical science research.

The award will be presented biennially to distinguished scientists who have made outstanding achievements and contributions in the field of computational physical science—spanning physics, chemistry, and materials science.

About Professor Michele Parrinello

"Do not be afraid of new things. I see it many times when we discuss a new thing that young people are scared to go against the mainstream a little bit, thinking what is going to happen to me and so on. Be confident that what you do is meaningful, and do not be afraid, do not listen too much to what other people have to say.”

——Professor Michele Parrinello

Born in Messina in 1945, he received his degree from the University of Bologna and is currently affiliated with the Italian Institute of Technology. Professor Parrinello is known for his many technical innovations in the field of atomistic simulations and for a wealth of interdisciplinary applications ranging from materials science to chemistry and biology. Together with Roberto Car, he introduced ab initio molecular dynamics, also known as the Car–Parrinello method, marking the beginning of a new era both in the area of electronic structure calculations and in molecular dynamics simulations. He is also known for the Parrinello–Rahman method, which allows crystalline phase transitions to be studied by molecular dynamics. More recently, he has introduced metadynamics for the study of rare events and the calculation of free energies.

For his work, he has been awarded many prizes and honorary degrees. He is a member of numerous academies and learned societies, including the German Berlin-Brandenburgische Akademie der Wissenschaften, the British Royal Society, and the Italian Accademia Nazionale dei Lincei, which is the major academy in his home country of Italy.

Award Committee

The award committee will be chaired by Professor Xin-Gao Gong, a computational condensed matter physicist, academician of the Chinese Academy of Sciences, and professor at the Department of Physics, Fudan University. Professor Xin-Gao Gong will lead a panel of several senior experts in the field to oversee the evaluation and selection process. The Institute for Computational Physical Sciences at Fudan University (Shanghai, China), led by Professor Xin-Gao Gong, will serve as the supporting institute for the award.

"We hope the Michele Parrinello Award will recognize scientists who have made significant contributions to the field of computational condensed matter physics and at the same time set a benchmark for the younger generation, providing clear direction for their pursuit—this is precisely the original intention behind establishing the award."

——Professor Xin-Gao Gong

The first edition of the award was officially launched on 1 November 2025. Nominations will be accepted before the end of March 2026. For further details, please visit mparrinelloaward.org.

About the MDPI Sustainability Foundation and MDPI Awards

The Michele Parrinello Award is part of the MDPI Sustainability Foundation, which is dedicated to advancing sustainable development through scientific progress and global collaboration. The foundation also oversees the World Sustainability Award, the Emerging Sustainability Leader Award, and the Tu Youyou Award. The establishment of the Michele Parrinello Award will further enrich the existing award portfolio, providing continued and diversified financial support to outstanding professionals across various fields. 

In addition to these foundation-level awards, MDPI journals also recognize outstanding contributions through a range of honors, including Best Paper Awards, Outstanding Reviewer Awards, Young Investigator Awards, Travel Awards, Best PhD Thesis Awards, Editor of Distinction Awards, and others. These initiatives aim to recognize excellence across disciplines and career stages, contributing to the long-term vitality and sustainability of scientific research.

Find more information on awards here.

Editor’s Choice Articles are selected based on suggestions from the academic editors of Pharmaceutics (ISSN: 1999-4923). The editors select a small number of published articles that they consider particularly interesting to our readers or important in their respective fields of research. You are therefore invited to read the Editor’s Choice Articles, a curated list of high-quality articles published in Pharmaceutics in April 2025. The full list of Editor’s Choice Articles can be viewed via the following link: https://www.mdpi.com/journal/pharmaceutics/editors_choice.

1. “PLA-Based Electrospun Nanofibrous Mats Towards Application as Antibiotic Carriers: Processing Parameters, Fabrication and Characterization”
by Evi Christodoulou, Anastasia Chondromatidou, Nikolaos D. Bikiaris, Evangelia Balla, Marilena Vlachou, Panagiotis Barmpalexis and Dimitrios N. Bikiaris
Pharmaceutics 2025, 17(5), 589; https://doi.org/10.3390/pharmaceutics17050589
Editor’s highlight: “This interesting study demonstrates that star-shaped PLA-pentaerythritol (PLA-PE) copolymer nanofibers significantly outperform conventional linear PLA for transdermal antibiotic delivery systems. The star-shaped architecture enhances porosity, drug loading capacity, and drug release rates, while enabling faster biodegradation for controlled drug delivery. This innovation opens new possibilities for advanced wound dressing and anti-infective therapeutic applications.”

2. “Advances in Drug Delivery Integrated with Regenerative Medicine: Innovations, Challenges, and Future Frontiers”
by Manoochehr Rasekh, Muhammad Sohail Arshad and Zeeshan Ahmad
Pharmaceutics 2025, 17(4), 456; https://doi.org/10.3390/pharmaceutics17040456
Editor’s highlight: “This comprehensive review examines the convergence of advanced drug delivery systems with regenerative medicine technologies, highlighting groundbreaking approaches for tissue repair and disease treatment. Key topics include biomaterial integration enabling controlled release systems with enhanced therapeutic precision, cell-based therapies, emerging technologies such as 3D bioprinting and electrospinning, and clinical applications. This interdisciplinary approach accelerates personalized medicine and addresses major challenges in regenerative therapy.”

3. “Use of Computational Intelligence in Customizing Drug Release from 3D-Printed Products: A Comprehensive Review”
by Fantahun Molla Kassa, Souha H. Youssef, Yunmei Song and Sanjay Garg
Pharmaceutics 2025, 17(5), 551; https://doi.org/10.3390/pharmaceutics17050551
Editor’s highlight: “This review explores how computational intelligence and machine learning are transforming personalized medicine through advanced 3D printing technology. Key advances include predictive modeling, customized formulations, quality optimization with real-time quality control and manufacturing process enhancement, and clinical translation. This convergence of AI and 3D printing is contributing to the development of on-demand, personalized pharmaceutical manufacturing.”

4. “Anti-Candida Activity of Cysteine-Modified Amidated Decoralin in the Presence of Engineered Nanomaterials”
by Vânia Rocha, Helena Almeida, Bruno Sarmento and José das Neves
Pharmaceutics 2025, 17(4), 460; https://doi.org/10.3390/pharmaceutics17040460
Editor’s highlight: “The study highlights the potential and challenges of peptide-based antifungal treatments by offering precise, methodologically sound insights into the interactions between antimicrobial peptides and nanomaterials. It is a significant addition to the field considering its methodical evaluation and clinical applicability.”

5. “Salicylic Acid-Mediated Silver Nanoparticle Green Synthesis: Characterization, Enhanced Antimicrobial, and Antibiofilm Efficacy”
by Jingqing Zhang, Yuxu Chen, Yuanyu Xu, Zhimin Zhao and Xinjun Xu
Pharmaceutics 2025, 17(4), 532; https://doi.org/10.3390/pharmaceutics17040532
Editor’s highlight: “The submitted manuscript presents a compelling and timely contribution to the field of nanobiotechnology by introducing a rapid, sustainable, and highly effective biogenic synthesis method for salicylic acid-mediated silver nanoparticles (SA-AgNPs). To confirm the Editor's Choice designation, this is supported by several key strengths:

• Innovative and Environmentally Friendly Synthesis Approach: The study employs salicylic acid as both a reducing and capping agent, offering a simplified, green, and reproducible synthetic route. This dual functionality significantly advances current methodologies by eliminating the need for toxic chemicals and complex procedures, aligning with global priorities in sustainable nanomaterial production.
• Comprehensive Multimodal Characterization: The nanoparticles were rigorously analyzed using a broad suite of characterization techniques (UV Vis, DLS, SEM-EDS, TEM, XRD, FTIR, TGA/DSC). This thorough methodological framework reinforces the scientific robustness of the findings and ensures high reproducibility, which is essential for translational research.
• Exceptional Antibacterial Efficacy and Mechanistic Insight: SA-AgNPs demonstrated strong inhibitory effects against both Gram-positive and Gram-negative pathogens, including clinically relevant drug-resistant strains such as MRSA and methicillin-resistant Staphylococcus epidermidis. The study not only reports impressive MIC values and killing efficiencies but also elucidates the underlying antibacterial mechanism, showing membrane permeability disruption and induction of bacterial apoptosis. This mechanistic clarity enhances the manuscript's scientific impact.
• High Relevance to Global Health and Biomedical Applications: The demonstrated ability of SA-AgNPs to inhibit 95.61% of MRSA biofilm formation highlights their strong potential for integration into antibacterial coatings, implantable medical devices, and advanced wound dressings. Given the urgent need for alternatives to conventional antibiotics in the face of rising antimicrobial resistance, the findings have substantial translational and societal value.
• Alignment with Editorial Priorities: The manuscript combines methodological novelty, environmental sustainability, mechanistic depth, and direct application potential qualities that strongly align with the standards typically recognized by the Editor's Choice designation. Its broad relevance across materials science, microbiology, and biomedical engineering makes it particularly impactful for the journal's readership.

In summary, the work offers significant scientific advancement and a promising platform for next-generation nano-antibiotic technologies. The rigor, innovation, and application-oriented relevance of the study make it an excellent candidate for selection as an Editor's Choice feature.”

6. “Carbon Dots as a Fluorescent Nanosystem for Crossing the Blood–Brain Barrier with Plausible Application in Neurological Diseases”
by Catarina Araújo, Raquel O. Rodrigues, Manuel Bañobre-López, Adrián M. T. Silva and Rui S. Ribeiro
Pharmaceutics 2025, 17(4), 477; https://doi.org/10.3390/pharmaceutics17040477
Editor’s highlight: “This manuscript presents a well-designed and carefully executed study on fluoride-doped carbon dots for brain-targeted theranostic applications. The authors provide a thorough characterization, demonstrating that the NF-CDs possess well-defined nanoscale dimensions, high quantum yield, excitation-dependent fluorescence, and excellent colloidal and photostability.
The biological evaluation, particularly the demonstration of low cytotoxicity and BBB model permeability, is promising. However, it should be noted that carbon dots can potentially interfere with resazurin-based assays, and the study does not include a positive control to validate the cytotoxicity measurements. These points limit the confidence in the quantitative cytotoxicity data and should be addressed in future work.
Nonetheless, the study makes a significant contribution through its synthesis, characterization, and demonstration of BBB permeability. Overall, it is a high-quality and impactful piece of research that will be of interest to the nanomaterials and biomedical communities, and it is suitable for consideration as an Editor’s Choice Article.”

7. “Influence of Ionization and the Addition of Cyclodextrins and Hydrophilic Excipients on the Solubility of Benzthiazide, Isoxicam, and Piroxicam”
by Diego Lucero-Borja, Rebeca Ruiz, Elisabet Fuguet and Clara Ràfols
Pharmaceutics 2025, 17(5), 571; https://doi.org/10.3390/pharmaceutics17050571
Editor’s highlight: “The manuscript highlighted that the bioavailability of a drug depends, among other parameters, on solubility. The authors emphasize that one of the strategies used to enhance the solubility of sparingly soluble drugs is the use of excipients. Excipients can interact with the drug by increasing its solubility and/or stabilizing supersaturated solutions. Also, the authors underlined that some of the most common excipients are cyclodextrins and hydrophilic polymers. Dr. Lucero-Borja et al. based their study on the effect of two cyclodextrins (captisol and cavasol) and three hydrophilic polymers (klucel, kollidon and plasdone S630) on the solubility of three ionizable drugs (benzthiazide, isoxicam, and piroxicam). They evaluated this at biorelevant pH values, using two complementary techniques. The methods they used was the solubility enhancement by evaluating the comparison of the solubility with and without the presence of excipients through the shake-flask and CheqSol methodology. The results of the authors are very interesting. Dr. Lucero-Borja et al. showed that Captisol and cavasol slightly increase the concentration of the neutral species of the drugs in the solution before precipitation begins, although they do not enhance the supersaturation duration nor the thermodynamic solubility of the drugs. They showed also that the increase in solubility in the presence of cyclodextrins is mainly caused by the ionization state of the drug. Hydrophilic polymers not only improve thermodynamic solubility but also the extent and the duration of the supersaturation. Also, they observed that some metastable forms are observed for benzthiazide and isoxicam in the presence of kollidon and plasdone S630. The authors drew the conclusions that the shake-flask method enabled the evaluation of thermodynamic solubility both in the absence and presence of excipients. Meanwhile, the CheqSol method provided insights into the presence of supersaturated solutions. Different behavior was observed depending on the nature of the excipient.” 

We have expanded our open access portfolio with eight new journals publishing their inaugural issues in December 2025, as well as three journal transfers. These additions span physical sciences, social sciences, arts and humanities, environmental and Earth sciences, medicine and pharmacology, and public health and healthcare. We extend our sincere thanks to the Editors-in-Chief, Associate Editors, and Editorial Board Members who are shaping these journals’ direction. All journals uphold strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

We would like to thank everyone who has supported the development of open access publishing. If you would like to create more new journals, you are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com).

MDPI is excited to announce its participation as an exhibitor at the 2026 Society For Biomaterials Annual Meeting & Exposition (SFB 2026), taking place in Atlanta, USA, from 25 to 28 March 2026.

The Society For Biomaterials (SFB)’s Annual Meeting is the preeminent conference for biomaterials science. Each year, the Society provides a diverse program of sessions, panels, and workshops relating to special interest groups, specific topics, and important issues. The meeting is a welcoming community of academics, industry leaders, scientists, and students, networking and discussing the latest research and innovations in the field. The Annual Meeting provides an academic and social environment for connection and knowledge to be obtained by each individual.

The theme for the SFB 2026 Annual Meeting is Biomaterials at the Crossroads: Connecting Science, Industry, and Innovation. This is where the future of biomaterials unfolds!

The following MDPI journals will be presented at the conference:

• Bioengineering;
• Journal of Functional Biomaterials;
• Biomolecules;
• Journal of Pharmaceutical and BioTech Industry;
• Prosthesis;
• Materials;
• Future Pharmacology;
• Pharmaceutics;
• Biomedicines.

If you are attending this conference, please feel free to contact us. Our delegates look forward to meeting you in person at booth #401 and answering any questions that you may have. For more information about the conference, please visit the following link: https://meetings.biomaterials.org/.

We are pleased to announce updates to our article template, aimed at improving the readability and visual appeal of our publications. The following updates will be applied to articles published in volumes in 2026, starting from 19 December 2025.

Left information bar:

• Updated the logo and URL for “Check for updates”;
• Removed the “Citation” section (Note: Citation details remain accessible via “Cite” in the online article version);
• Changed the link in “Copyright” to a hyperlink format.

Footer:

• Added a DOI link at the bottom-right corner of each page.

The updated template is now available for download from the Instructions for Authors page of each journal.

We hope that the new version of the template will provide users with better experience and make the process more convenient.

For any questions or suggestions, please contact our production team at production@mdpi.com.

Editor’s Choice Articles are selected based on suggestions from the academic editors of Pharmaceutics (ISSN: 1999-4923). The editors select a small number of published articles that they consider particularly interesting to our readers or important in their respective fields of research. You are therefore invited to read the Editor’s Choice Articles, a curated list of high-quality articles published in Pharmaceutics in March 2025. The full list of Editor’s Choice Articles can be viewed via the following link: https://www.mdpi.com/journal/pharmaceutics/editors_choice.

1. “Development of Inhalable Bacteriophage Liposomes Against Pseudomonas aeruginosa”
by Shruti S. Sawant, Maizbha Uddin Ahmed, Nathan-Gautham Gantala and Caitlin Chiu
Pharmaceutics 2025, 17(4), 405; https://doi.org/10.3390/pharmaceutics17040405
Editor’s highlight: The article investigates alternative therapeutic strategies to conventional antibiotics for combating major respiratory pathogens such as Pseudomonas aeruginosa. In this study, the authors developed liposome-encapsulated bacteriophage formulations intended for pulmonary delivery via nebulization.
The findings are particularly compelling. Formulations exhibiting favorable encapsulation efficiency (58 ± 6.02%) achieved a sustained and controlled release of phages over a 10-hour period. Furthermore, liposomal encapsulation markedly mitigated phage viability loss during nebulization, decreasing from 1.55 ± 0.04 log in phage suspensions to 1.08 ± 0.05 log in liposome-encapsulated preparations.
The authors concluded that liposomal encapsulation not only resulted in a twofold reduction in phage cellular uptake but also prolonged extracellular phage retention within human lung epithelial cell monolayers. Collectively, these results demonstrate that liposomal encapsulation enhances phage stability and bioavailability, thereby improving their potential for antibacterial efficacy.

2. “Simvastatin-Loaded Chitosan-Functionalized PLGA Nanoparticles: Characterization and Use in Intimal Hyperplasia Therapy”
by Ashley A. Peters, Chanpreet Kaur, Maleen Cabe, Kelly A. Langert, Kristopher Maier and Vivian Gahtan 
Pharmaceutics 2025, 17(3), 391; https://doi.org/10.3390/pharmaceutics17030391
Editor’s highlight: In this article chitosan-functionalized PLGA nanoparticles loaded with simvastatin (SL-cNPs) were developed to treat intimal hyperplasia after vascular interventions. When combined with oral simvastatin, local SL-cNPs delivery significantly reduced intimal hyperplasia in rats by targeting endothelial and smooth muscle cells and modulating key vascular genes.
This dual approach minimizes systemic side effects and enhances vascular repair, but optimal benefit required both local and systemic therapy. The strategy points to a promising direction for improving outcomes and reducing restenosis in peripheral arterial disease.

3. “Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies”
by Jurga Bernatoniene, Mindaugas Plieskis and Kestutis Petrikonis
Pharmaceutics 2025, 17(3), 352; https://doi.org/10.3390/pharmaceutics17030352
Editor’s highlight: This is a review article that discusses the current state, applications, and transformative potential of 3D printing and nanotechnology in neurological treatment. 3D printing technology now integrates nanomaterials and nanodevices to deliver drugs precisely to the central nervous system, enabling personalized treatment of neurological diseases. This breakthrough allows multi-ingredient combinations in single tablets with programmable release kinetics, improving CNS drug delivery across the blood-brain barrier.
Key advantages include better patient compliance through reduced dosing, customizable formulations, and lower systemic toxicity. While production costs and regulatory pathways remain challenges, advances in materials science promise rapid clinical translation, particularly benefiting patients with swallowing difficulties and those requiring narrow therapeutic windows.

4. “The Role of Natural Deep Eutectic Solvents in a Hydrogel Formulation Containing Lidocaine”
by Feria Hasanpour, Mária Budai-Szűcs, Anita Kovács, Anita Kovács, Orsolya Jójárt-Laczkovich, Boglárka Szalai, Branimir Pavlić, Péter Simon, Levente Törteli and Szilvia Berkó
Pharmaceutics 2025, 17(3), 324; https://doi.org/10.3390/pharmaceutics17030324
Editor’s highlight: In this article researchers developed a Natural Deep Eutectic Solvents (NADESs) hydrogel containing lidocaine using green chemistry principles—choline chloride and citric acid—delivering 50% faster drug release and superior skin permeation compared to conventional ointments. The formulation achieves complete dissolution in 5 minutes with validated chemical stability and minimal skin irritation.
This sustainable, biodegradable approach offers potentially faster anesthesia onset (15-30 minutes) than EMLA cream while maintaining excellent skin barrier protection. With natural, inexpensive raw materials and scalable manufacturing, NADESs-hydrogel represents a cost-effective alternative for topical anesthesia, chronic pain management, and pediatric procedures.

5. “Analysis of Polymer/siRNA Nanoparticle Efficacy and Biocompatibility in 3D Air–Liquid Interface Culture Compared to 2D Cell Culture”
by Sandra Noske, Martin Krueger, Alexander Ewe and Achim Aigner
Pharmaceutics 2025, 17(3), 339; https://doi.org/10.3390/pharmaceutics17030339
Editor’s highlight: The study bridges polymer chemistry, nanomedicine, and advanced in vitro modeling, offering practical guidance for developing safe and effective siRNA nanocarriers. Its novelty, rigor, and translational potential make it a strong candidate for Editor’s Choice recognition.
This article exemplifies the Pharmaceutics mission to promote innovative and translational research in pharmaceutical sciences. It stands out through:

• Innovation – Introduction of a novel fluoroalkyl-modified PEI polymer for siRNA delivery;
• Methodological Strength – A direct, systematic comparison of 2D vs. 3D ALI culture systems, addressing a critical challenge in nanocarrier evaluation;
• Relevance – Direct applicability to pulmonary RNA therapeutics, an area of growing importance;
• Scientific Contribution – Identification of polymer structure–activity relationships and demonstration of ALI models as predictive tools for nanoparticle efficacy and biocompatibility;
• Quality and Clarity – Excellent scientific communication and data integrity.

6. “Nasal Administration of a Nanoemulsion Based on Methyl Ferulate and Eugenol Encapsulated in Chitosan Oleate: Uptake Studies in the Central Nervous System”
by Giada Botti, Giada Botti, Alessandro Dalpiaz, Luca Randi, Maria Cristina Bonferoni, Sara Perteghella, Sarah Beggiato, Luca Ferraro, Barbara Pavan and Milena Sorrenti
Pharmaceutics 2025, 17(3), 367; https://doi.org/10.3390/pharmaceutics17030367
Editor’s highlight: The manuscript is well-structured and presents a strong scientific rationale. The proposed nanoemulsions are thoroughly characterized from a physicochemical perspective and subsequently evaluated both in vitro and in vivo. The study is comprehensive, demonstrating a well-conceived research design, rigorous experimental execution, and robust characterization and application results. Overall, this work represents an excellent example of high-quality pharmaceutical research and fully merits consideration for the Editor’s Choice designation.

7. “Nanotechnology-Based Therapies for Preventing Post-Surgical Adhesions”
by Zi Yi Teo, Samyuktha Dhanalakshmi Senthilkumar and Dinesh Kumar Srinivasan
Pharmaceutics 2025, 17(3), 389; https://doi.org/10.3390/pharmaceutics17030389
Editor’s highlight: This review addresses the challenge of postoperative adhesions—common complications arising from surgery that can lead to serious outcomes such as pain and intestinal obstruction. While several prevention strategies currently exist, many are associated with side effects. In contrast, nanotherapeutics present a promising alternative, although they remain in the early stages of development. This article examines current nanotherapeutic approaches for adhesion prevention and explores their regulatory, safety, and ethical considerations, offering a comprehensive overview of the field's current progress.

8. “Targeting Neuroinflammation in Central Nervous System Diseases by Oral Delivery of Lipid Nanoparticles”
by Yuan Zou, Jing Zhang, Longmin Chen, Qianqian Xu, Sheng Yao and Hong Chen
Pharmaceutics 2025, 17(3), 388; https://doi.org/10.3390/pharmaceutics17030388
Editor’s highlight: This review provides a thorough and timely overview of recent progress on oral lipid nanoparticles as emerging carriers for modulating neuroinflammation in central nervous system disorders. By clearly outlining the challenges posed by the blood–brain barrier and highlighting how orally administered LNPs can enhance bioavailability, improve targeting, and support therapeutic efficacy, the authors offer valuable insight into a rapidly evolving field. The article’s balanced discussion of mechanisms, formulation strategies, and clinical relevance makes it an impactful and well-structured contribution, well suited for Editor’s Choice recognition.

On 17 December 2025, MDPI and Pharmaceutics (ISSN: 1999-4923) will host a webinar titled “Extemporaneous Formulations: Filling the Gap in the Pharmaceutical Industry with Personalized Medicines”.

This event will bring together distinguished experts and practitioners to discuss the evolving role of customised medications within modern healthcare.

Extemporaneous formulations embody the true essence of personalised medicine—allowing for tailored treatments that respond to specific patient needs when industrially manufactured products are unavailable or unsuitable. Recent advances in compounding technologies, materials, and regulatory approaches have strengthened the scientific foundation of these preparations, ensuring higher standards of quality, safety, and reproducibility.

At the same time, this field continues to face challenges—from standardisation and scalability to ensuring consistent therapeutic outcomes. Through this webinar, we aim to explore how innovation, collaboration, and patient-centred thinking can transform these challenges into opportunities for growth and global health improvement.

Date: 17 December 2025
Time: 4:00 p.m. CET | 10:00 a.m. EST
Webinar ID: 851 6540 3655

Register now for free!

Program:

After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic or institutional email addresses will be prioritised.

If you are unable to attend, feel free to register nonetheless; we will inform you once a recording of the webinar becomes available.

Webinar Chair and Keynote Speakers:

• Prof. Dr. Nunzio Denora, Department of Pharmacy, Pharmaceutical Sciences, University of Bari Aldo Moro, Italy;
• Prof. Dr. Milap Nahata, Pediatrics and Internal Medicine at the College of Medicine, Ohio State University, USA;
• Dr. Karolina Dziemidowicz, School of Pharmacy, University College London, United Kingdom;
• Dr. Antonio Lopalco, Department of Pharmacy, Pharmaceutical Sciences, University of Bari Aldo Moro, Italy.

Relevant Special Issue:
“Extemporaneous Formulations: Filling the Gap in the Pharmaceutical Industry with Personalized Medicines, 2nd Edition”
Guest Editors: Dr. Antonio Lopalco and Prof. Dr. Nunzio Denora
Deadline for Manuscript Submission: 31 May 2026

For more information about this webinar, please visit the following link: https://sciforum.net/event/Pharmaceutics-5.

If you have any questions about this webinar, please contact:  journal.webinar@mdpi.com.

Pharmaceutics Webinar Secretariat